Business Briefs
NATION
Genentech stands still on blindness treatments
WASHINGTON — What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?
In the case of Genentech Inc. , nothing.
The company declined to seek federal approval for the cheaper drug, Avastin , to...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
